Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India; NDC 62756-970-83
Published November 9, 2022 · Recall initiated: October 18, 2022
Summary
FDA records drug Class II recall D-0024-2023, published November 9, 2022 and initiated October 18, 2022. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Terminated; Reported quantity: N/A; Lot: Lot #: DNC1129A, Exp 06/2023 Lot #: DNC1740A, Exp 09/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Foreign Substance
What to do
Voluntary: Firm initiated · Letter
Get an email if BUPRENORPHINE AND NALOXONE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BUPRENORPHINE AND NALOXONE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Distributor
- Nationwide with the United States
- UPC
- 0362756969834
- Lot
- Lot #: DNC1129A, Exp 06/2023 Lot #: DNC1740A, Exp 09/2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDASusvimo (ranibizumab injection), 100mg/mL, sold together as a) carton containing One Susvimo single-dose vialNovember 9, 2022
- FDAACETYLCYSTEINE OPTH 10% Solution, 15 mL droptainers, Rx only, Vital Care Compounder, 115 S. 40th Ave.,November 9, 2022
- FDAda Vinci X (IS4200) and Xi (IS4000) systems, which consists of finished devices Surgeon Console (SSC), PatientNovember 2, 2022
- FDALINEAR 7.5Fr. 40cc IAB with Accessories (APA), Model No. 0684-00-0480-02. intra-aortic balloon catheter.November 2, 2022
- FDAConvaTec Active Life, One-Piece Drainable Pouch, 3/4-2 1/2 in., 19-64mm, REF 400598. For the management ofNovember 2, 2022
- FDABuprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film,July 14, 2021
Questions about this recall
Was Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India; NDC 62756-970-83 recalled?
Yes. FDA published recall D-0024-2023 on November 9, 2022. Reported hazard: Presence of Foreign Substance
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BUPRENORPHINE AND NALOXONE. UPC: 0362756969834.